BIOMAT Database Logo BIOMAT Database Logo

An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone. 1990

L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Department of Surgery, University of Minnesota, Minneapolis 55455.

We studied the incidence of biopsy-proven, acute rejection episodes occurring after 1 year posttransplant in cadaver renal allograft recipients. The 328 patients evaluated were given three immunosuppressive drug protocols. Group I (transplanted 9/80-6/84) (n = 75) received azathioprine, prednisone (P), and antilymphoblast globulin; group II (transplanted 9/80-6/84) (n = 83) received cyclosporine and P; group III (transplanted 7/84-12/86) (n = 170) received ALG, AZA, CsA, and P (sequential therapy). The incidence of first acute rejection episodes occurring up to 1 year posttransplant was 55% in group I and 35% in groups II and III. The incidence of late (greater than 1 year) acute rejection episodes was 6.5% in group I, 2.5% in group II, and 9.5% in group III (group II vs. III, P = 0.02). In group III, 50% of the late rejections were first, 44% second, and 6% third. The primary etiologies of this increased incidence of late acute rejection may have included subtherapeutic CsA levels and lower P doses. Sequential immunosuppressive therapy has been shown to be advantageous in the first posttransplant year. However, unless adequate immunosuppression is maintained, this approach can be associated with a significantly increased incidence of late acute rejection.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002102 Cadaver A dead body, usually a human body. Corpse,Cadavers,Corpses
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
June 1998, Transplantation proceedings,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Immunosuppression with cyclosporine, azathioprine, and prednisolone in cadaver renal allograft recipients.
February 1987, Transplantation proceedings,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy.
February 1991, Transplantation,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Delayed acute rejection episodes in cyclosporine-treated renal transplant recipients.
April 1985, Annals of surgery,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Delayed-type hypersensitivity-like mechanisms dominate late acute rejection episodes in renal allograft recipients.
April 1996, Transplantation,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Acute irreversible rejection after withdrawal of azathioprine in renal allograft recipients.
July 1981, The Tokai journal of experimental and clinical medicine,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients.
February 1989, Transplantation,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine.
August 1999, Clinical transplantation,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Azathioprine dosage schedule and rejection episodes in renal transplant recipients.
October 1982, British journal of clinical pharmacology,
L E Wrenshall, and A J Matas, and D M Canafax, and D I Min, and R J Sibley, and D L Dunn, and W D Payne, and D E Sutherland, and J S Najarian
Conversion from cyclosporine to azathioprine in renal allograft recipients.
December 1984, Transplantation,
Copied contents to your clipboard!